Host-directed therapies for infectious diseases

Current status, recent progress, and future prospects

Alimuddin Zumla, Martin Rao, Robert S. Wallis, Stefan H E Kaufmann, Roxana Rustomjee, Peter Mwaba, Cris Vilaplana, Dorothy Yeboah-Manu, Jeremiah Chakaya, Giuseppe Ippolito, Esam Azhar, Michael Hoelscher, Markus Maeurer

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Despite extensive global efforts in the fight against killer infectious diseases, they still cause one in four deaths worldwide and are important causes of long-term functional disability arising from tissue damage. The continuing epidemics of tuberculosis, HIV, malaria, and influenza, and the emergence of novel zoonotic pathogens represent major clinical management challenges worldwide. Newer approaches to improving treatment outcomes are needed to reduce the high morbidity and mortality caused by infectious diseases. Recent insights into pathogen-host interactions, pathogenesis, inflammatory pathways, and the host's innate and acquired immune responses are leading to identification and development of a wide range of host-directed therapies with different mechanisms of action. Host-directed therapeutic strategies are now becoming viable adjuncts to standard antimicrobial treatment. Host-directed therapies include commonly used drugs for non-communicable diseases with good safety profiles, immunomodulatory agents, biologics (eg monoclonal antibodies), nutritional products, and cellular therapy using the patient's own immune or bone marrow mesenchymal stromal cells. We discuss clinically relevant examples of progress in identifying host-directed therapies as adjunct treatment options for bacterial, viral, and parasitic infectious diseases.

Original languageEnglish
Pages (from-to)e47-e63
JournalThe Lancet Infectious Diseases
Volume16
Issue number4
DOIs
Publication statusPublished - Apr 1 2016

Fingerprint

Communicable Diseases
Mesenchymal Stromal Cells
Therapeutics
Host-Pathogen Interactions
Parasitic Diseases
Zoonoses
Biological Factors
Innate Immunity
Human Influenza
Malaria
Tuberculosis
Monoclonal Antibodies
HIV
Morbidity
Safety
Mortality
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Zumla, A., Rao, M., Wallis, R. S., Kaufmann, S. H. E., Rustomjee, R., Mwaba, P., ... Maeurer, M. (2016). Host-directed therapies for infectious diseases: Current status, recent progress, and future prospects. The Lancet Infectious Diseases, 16(4), e47-e63. https://doi.org/10.1016/S1473-3099(16)00078-5

Host-directed therapies for infectious diseases : Current status, recent progress, and future prospects. / Zumla, Alimuddin; Rao, Martin; Wallis, Robert S.; Kaufmann, Stefan H E; Rustomjee, Roxana; Mwaba, Peter; Vilaplana, Cris; Yeboah-Manu, Dorothy; Chakaya, Jeremiah; Ippolito, Giuseppe; Azhar, Esam; Hoelscher, Michael; Maeurer, Markus.

In: The Lancet Infectious Diseases, Vol. 16, No. 4, 01.04.2016, p. e47-e63.

Research output: Contribution to journalArticle

Zumla, A, Rao, M, Wallis, RS, Kaufmann, SHE, Rustomjee, R, Mwaba, P, Vilaplana, C, Yeboah-Manu, D, Chakaya, J, Ippolito, G, Azhar, E, Hoelscher, M & Maeurer, M 2016, 'Host-directed therapies for infectious diseases: Current status, recent progress, and future prospects', The Lancet Infectious Diseases, vol. 16, no. 4, pp. e47-e63. https://doi.org/10.1016/S1473-3099(16)00078-5
Zumla, Alimuddin ; Rao, Martin ; Wallis, Robert S. ; Kaufmann, Stefan H E ; Rustomjee, Roxana ; Mwaba, Peter ; Vilaplana, Cris ; Yeboah-Manu, Dorothy ; Chakaya, Jeremiah ; Ippolito, Giuseppe ; Azhar, Esam ; Hoelscher, Michael ; Maeurer, Markus. / Host-directed therapies for infectious diseases : Current status, recent progress, and future prospects. In: The Lancet Infectious Diseases. 2016 ; Vol. 16, No. 4. pp. e47-e63.
@article{f9636f57818a4efdb773f561b4f10df9,
title = "Host-directed therapies for infectious diseases: Current status, recent progress, and future prospects",
abstract = "Despite extensive global efforts in the fight against killer infectious diseases, they still cause one in four deaths worldwide and are important causes of long-term functional disability arising from tissue damage. The continuing epidemics of tuberculosis, HIV, malaria, and influenza, and the emergence of novel zoonotic pathogens represent major clinical management challenges worldwide. Newer approaches to improving treatment outcomes are needed to reduce the high morbidity and mortality caused by infectious diseases. Recent insights into pathogen-host interactions, pathogenesis, inflammatory pathways, and the host's innate and acquired immune responses are leading to identification and development of a wide range of host-directed therapies with different mechanisms of action. Host-directed therapeutic strategies are now becoming viable adjuncts to standard antimicrobial treatment. Host-directed therapies include commonly used drugs for non-communicable diseases with good safety profiles, immunomodulatory agents, biologics (eg monoclonal antibodies), nutritional products, and cellular therapy using the patient's own immune or bone marrow mesenchymal stromal cells. We discuss clinically relevant examples of progress in identifying host-directed therapies as adjunct treatment options for bacterial, viral, and parasitic infectious diseases.",
author = "Alimuddin Zumla and Martin Rao and Wallis, {Robert S.} and Kaufmann, {Stefan H E} and Roxana Rustomjee and Peter Mwaba and Cris Vilaplana and Dorothy Yeboah-Manu and Jeremiah Chakaya and Giuseppe Ippolito and Esam Azhar and Michael Hoelscher and Markus Maeurer",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/S1473-3099(16)00078-5",
language = "English",
volume = "16",
pages = "e47--e63",
journal = "The Lancet Infectious Diseases",
issn = "1473-3099",
publisher = "Lancet Publishing Group",
number = "4",

}

TY - JOUR

T1 - Host-directed therapies for infectious diseases

T2 - Current status, recent progress, and future prospects

AU - Zumla, Alimuddin

AU - Rao, Martin

AU - Wallis, Robert S.

AU - Kaufmann, Stefan H E

AU - Rustomjee, Roxana

AU - Mwaba, Peter

AU - Vilaplana, Cris

AU - Yeboah-Manu, Dorothy

AU - Chakaya, Jeremiah

AU - Ippolito, Giuseppe

AU - Azhar, Esam

AU - Hoelscher, Michael

AU - Maeurer, Markus

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Despite extensive global efforts in the fight against killer infectious diseases, they still cause one in four deaths worldwide and are important causes of long-term functional disability arising from tissue damage. The continuing epidemics of tuberculosis, HIV, malaria, and influenza, and the emergence of novel zoonotic pathogens represent major clinical management challenges worldwide. Newer approaches to improving treatment outcomes are needed to reduce the high morbidity and mortality caused by infectious diseases. Recent insights into pathogen-host interactions, pathogenesis, inflammatory pathways, and the host's innate and acquired immune responses are leading to identification and development of a wide range of host-directed therapies with different mechanisms of action. Host-directed therapeutic strategies are now becoming viable adjuncts to standard antimicrobial treatment. Host-directed therapies include commonly used drugs for non-communicable diseases with good safety profiles, immunomodulatory agents, biologics (eg monoclonal antibodies), nutritional products, and cellular therapy using the patient's own immune or bone marrow mesenchymal stromal cells. We discuss clinically relevant examples of progress in identifying host-directed therapies as adjunct treatment options for bacterial, viral, and parasitic infectious diseases.

AB - Despite extensive global efforts in the fight against killer infectious diseases, they still cause one in four deaths worldwide and are important causes of long-term functional disability arising from tissue damage. The continuing epidemics of tuberculosis, HIV, malaria, and influenza, and the emergence of novel zoonotic pathogens represent major clinical management challenges worldwide. Newer approaches to improving treatment outcomes are needed to reduce the high morbidity and mortality caused by infectious diseases. Recent insights into pathogen-host interactions, pathogenesis, inflammatory pathways, and the host's innate and acquired immune responses are leading to identification and development of a wide range of host-directed therapies with different mechanisms of action. Host-directed therapeutic strategies are now becoming viable adjuncts to standard antimicrobial treatment. Host-directed therapies include commonly used drugs for non-communicable diseases with good safety profiles, immunomodulatory agents, biologics (eg monoclonal antibodies), nutritional products, and cellular therapy using the patient's own immune or bone marrow mesenchymal stromal cells. We discuss clinically relevant examples of progress in identifying host-directed therapies as adjunct treatment options for bacterial, viral, and parasitic infectious diseases.

UR - http://www.scopus.com/inward/record.url?scp=84962538329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962538329&partnerID=8YFLogxK

U2 - 10.1016/S1473-3099(16)00078-5

DO - 10.1016/S1473-3099(16)00078-5

M3 - Article

VL - 16

SP - e47-e63

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

SN - 1473-3099

IS - 4

ER -